[Activity Repor] The Joint Review Committee of Seven Academic Societies for the Promotion of Infectious Disease Therapy and Drug Discovery releases recommendations entitled, “The Need for a System that Allows Continued Research and Development of Therapeutic Agents, Vaccines, and Tests for Pandemics and Silent Pandemics: Background and Objectives.” (August 2, 2022)
date : 11/2/2022
Tags: AMR
The Joint Review Committee of Seven Academic Societies for the Promotion of Infectious Disease Therapy and Drug Discovery, for which AMR Alliance Japan (Secretariat: HGPI) is a cooperating member, has released recommendations on “The Need for a System that Allows Continued Research and Development of Therapeutic Agents, Vaccines, and Tests for Pandemics and Silent Pandemics: Background and Objectives.”
The recommendation can be found here.
*Available Only in Japanese
■The Joint Review Committee of Seven Academic Societies for the Promotion of Infectious Disease Therapy and Drug Discovery
The Joint Review Committee of Seven Academic Societies for the Promotion of Infectious Disease Therapy and Drug Discovery is comprised of The Japanese Society of Chemotherapy, The Japanese Association for Infectious Disease, The Japanese Society for Clinical Microbiology, The Japanese Society for Infection Prevention and Control, The Japanese Society for Bacteriology, The Pharmaceutical Society of Japan, and The Japanese Society of Veterinary Science. It investigates the promotion of infectious disease therapy and drug therapy from a medical perspective.
■AMR Alliance Japan
AMR Alliance Japan AMR was established in November 2018 as a multi-stakeholder, collaborative organization dedicated to the improvement of public health through the promotion of AMR countermeasures. As of August 2022, its members include MSD K.K., “Kodomo to Iryo” Project, Shionogi & Co., Ltd., Sumitomo-Pharma Co., Ltd., The Japanese Society of Antimicrobials for Animals, NISSUI Pharmaceutical Co., Ltd., Nippon Becton Dickson Co., Ltd., The Japan Medical Association, The Japanese Society for Medical Mycology, The Japanese Society of Pharmaceutical Health Care and Sciences, The Japanese Society of Chemotherapy, The Japanese Society for Infection Prevention and Control, The Japanese Association for Infectious Diseases, The Japanese Society for Pediatric Infectious Diseases, The Japan Pharmaceutical Manufacturers Association, The Japanese Society of Therapeutic Drug Monitoring, The Japanese Society of Hospital Pharmacists, The Pharmaceutical Society of Japan; The Japan Pharmaceutical Association, The Japanese Society for Clinical Microbiology, bioMérieux Japan Ltd., Himeji City, Pfizer Japan Inc., and Meiji Seika Pharma Co., Ltd. The Health and Global Policy Institute serves as the Secretariat of AMR Alliance Japan.
Top Research & Recommendations Posts
- [Research Report] Building a Mental Health Program for Children and Measuring its Effectiveness (June 16, 2022)
- [Research Report] 2019 Survey on Healthcare in Japan
- [Policy Recommendations] Developing a National Health and Climate Strategy for Japan (June 26, 2024)
- [Announcement] A Turning Point Towards Building Green Healthcare Systems (June 5, 2024)
- [Research Report] The 2023 Public Opinion Survey on Satisfaction in Healthcare in Japan and Healthcare Applications of Generative AI (January 11, 2024)
- [Policy Recommendations] Obesity Control Promotion Project 2023 “The Next Steps for Engaging and Cooperating with Patients, Citizens, and Communities for Implements of Obesity Control Measurements” (April 8, 2024)
- [Policy Recommendations] Kidney Disease Control Promotion Project 2023 “Establishing Kidney Disease Control Measures with Patient, Citizen, and Community Engagement and Collaboration” Policy Recommendations, a Collection of Good Practices of Chronic Kidney Disease (CKD) and Control Measures in Local Governments (February 14, 2024)
- [New Report] Policy Priorities for Super-Ageing Japan: Health Innovation and Economic Growth in the COVID-19 Pandemic Era (February 24, 2021)
- [Report and Recommendations] Discussion Points in Healthcare DX Project Expert Panel Meeting (April 2, 2024)
- [Policy Recommendations] Achieving Equity in Multidisciplinary Pain Treatment and Support Systems for Pain Management (March 31, 2023)
Featured Posts
-
2024-10-07
[Registration Open] Planetary Health Expert Meeting “Building the Future of Healthcare: A Vision for Sustainable and Resilient Health Systems with GGHH” (November 5, 2024)
-
2024-10-09
[Registration Closed] (Webinar) The 128th HGPI Seminar “Viewing Healthcare Disparities Through the Lens of Breast Cancer Treatment” (October 29, 2024)
-
2024-10-24
[Event Report] HGPI Salon Special Edition “Overcoming Infectious Diseases through Partnership: Focusing on examples of promoting technology transfer of antimicrobial agents” (October 21, 2024)
-
2024-10-28
[Registration Open] (Hybrid Format) Public Symposium “Promoting CVD Control Based on the Needs of People Living with or Affected by Cardiovascular Diseases: Towards Effective Implementation of the Second Phase CVD Control Plans” (November 22, 2024)